Pelthos Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 9.00K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 14.00K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 6.50K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 20.50K shares.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 9.00K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | 29.50K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 0.00 shares 10-Q/A · filed 2026-08-13 | 20.50K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 14.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 20.50K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 6.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 6.50K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 0.00 shares 10-Q/A · filed 2026-08-13 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 0.00 shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |